Table 1.

Baseline demographics and patient characteristics

Characteristic200–300 mg400 mg500 mgTotal
(n = 4)(n = 36)(n = 7)(N = 47)
Age (y)
 Median48.557.062.057.0
 Range46–6526–8033–7126–80
Sex, n (%)
 Female2 (50)17 (47)3 (43)22 (47)
 Male2 (50)19 (53)4 (57)25 (53)
ECOG performance status, n (%)
 01 (25)19 (53)2 (29)22 (47)
 13 (75)17 (47)5 (71)25 (53)
Primary site of cancer, n (%)
 Cutaneous2 (50.0)23 (63.9)4 (57.1)29 (61.7)
 Mucosal02 (5.6)02 (4.3)
 Ocular1 (25.0)6 (16.7)1 (14.3)8 (17.0)
 Unknown1 (25.0)3 (8.3)04 (8.5)
 Other02 (5.6)2 (28.6)4 (8.5)
Melanoma subtype, n (%)
 Acral-lentiginous02 (5.6)02 (4.3)
 Desmoplastic01 (2.8)01 (2.1)
 Mucosal03 (8.3)1 (14.3)4 (8.5)
 Nodular1 (25)4 (11.1)1 (14.3)6 (12.8)
 Other1 (25)01 (14.3)2 (4.3)
 Superficial spreading1 (25)9 (25.0)1 (14.3)11 (23.4)
 Unknown1 (25)13 (36.1)3 (42.9)17 (36.2)
 Uveal04 (11.1)04 (8.5)

Abbreviation: ECOG, Eastern Cooperative Oncology Group.